Tranexamic acid explained — the hyperpigmentation ingredient dermatologists actually use.

Tranexamic acid is not a traditional skincare ingredient. It was developed as a haemostatic drug — a compound that helps blood clot — and was used for decades in surgery and to treat heavy menstrual bleeding. Its relevance to hyperpigmentation was discovered through an observation: patients taking oral tranexamic acid for other conditions reported significant improvement in melasma.

The topical form followed. It is now one of the better-evidenced options for uneven skin tone, post-inflammatory hyperpigmentation, and melasma, with a tolerability profile that makes it suitable for a wider range of skin types than many other brightening actives.

How it works

Melanin production in the skin is not a simple on/off switch. It is regulated by a cascade of signals, and tranexamic acid interrupts one of them at a specific point.

The relevant pathway begins with plasminogen — a protein involved in fibrinolysis (breaking down blood clots) but also present in the skin. UV exposure activates plasminogen into plasmin. Plasmin stimulates the release of arachidonic acid, which triggers prostaglandin synthesis. Prostaglandins signal melanocytes — the pigment-producing cells in the skin — to increase melanin output. They also enhance the activity of tyrosinase, the enzyme responsible for synthesising melanin.

Tranexamic acid works by blocking the lysine binding sites on plasminogen, preventing its conversion to plasmin. This interrupts the signalling cascade before it reaches the melanocyte. The result is reduced melanin stimulation via a mechanism that is distinct from the tyrosinase-inhibition pathway used by ingredients like alpha-arbutin, kojic acid, and vitamin C.

This means tranexamic acid can be used alongside tyrosinase inhibitors — the mechanisms are additive, not redundant.

Evidence

The majority of the clinical evidence involves concentrations of 2–5% in leave-on formulations applied once or twice daily. Results in controlled trials are consistent: statistically significant reduction in hyperpigmentation over 8–12 weeks, with outcomes comparable to 2% hydroquinone and superior tolerability.

A 2017 double-blind study comparing 3% tranexamic acid to 3% hydroquinone found equivalent efficacy at week 12 with significantly lower rates of adverse effects — including erythema, burning, and contact dermatitis — in the tranexamic acid group. Multiple studies since have confirmed the pattern: similar or slightly lower efficacy than hydroquinone at standard concentrations, meaningfully better tolerated.

Oral tranexamic acid at therapeutic doses (250–750 mg twice daily) shows faster and more pronounced effects than topical formulations, which makes sense given the systemic vs surface delivery. Topical use at evidence-backed concentrations produces clear benefit without the systemic exposure.

Tolerability and compatibility

Tranexamic acid is not an acid in the exfoliating sense. The name is taxonomic, not descriptive — it refers to the amino acid backbone of the molecule. It does not lower skin pH in the way AHAs or BHAs do. It does not cause the photosensitivity associated with exfoliating acids. It can be used morning or evening without SPF being an absolute requirement for its own function (though SPF matters enormously when treating any hyperpigmentation, because UV exposure continuously re-stimulates melanin production and undoes progress regardless of which active is being used).

It is compatible with niacinamide, vitamin C, AHAs, retinoids, and SPF. Sensitisation is rare.

Skin tone matters more for some hyperpigmentation ingredients than others. Tranexamic acid has a good tolerability record across skin tones, including deeper tones where some actives — particularly at higher concentrations — carry a risk of post-inflammatory hyperpigmentation if they provoke irritation.

How to use it

A 2–5% leave-on serum, applied once or twice daily, is the standard approach. It can be layered with niacinamide for a complementary multi-mechanism approach: niacinamide inhibits the transfer of melanin from melanocytes to keratinocytes at the surface while tranexamic acid reduces melanin production upstream.

Results at 2–5% take 8–12 weeks to be clearly visible. Consistency and SPF are the two most important variables.

The Lux & Glo position

The Niacinamide Boost Serum addresses uneven tone primarily through niacinamide's mechanism — melanin transfer inhibition and anti-inflammatory action. Tranexamic acid operates at a different point in the pathway. For skin dealing with persistent melasma or PIH that is slow to respond, a dedicated tranexamic acid formulation is a logical addition alongside the core ritual rather than a replacement for it.

The most effective protocol for hyperpigmentation is layered: SPF as the non-negotiable foundation, consistent barrier support, and one or two well-chosen actives targeting different points in the melanin pathway. Tranexamic acid fits into that framework without conflict.